Sacituzumab Govitecan Toxicity Outcomes In Arab Patients with Metastatic Breast Cancer

被引：0
|
作者：
Altarturi, Maymouna
Suleman, Kausar
AlSayed, Adhar
Al-Shamsi, Humaid
Alawadhi, Aydah
Basuliamn, Bassam
Alaklabi, Sabah
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-12-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-12-10
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Sacituzumab govitecan in metastatic Breast Cancer Optimal Interaction: ADC-based Therapy and Radiotherapy
    Schoellmann, Claudia
    BREAST CARE, 2024, 19 (04) : 236 - 238
  • [32] Sacituzumab govitecan-a new therapy for patients with triple-negative breast cancer
    Pogoda, Katarzyna
    Jagiello-Gruszfeld, Agnieszka
    Niwinska, Anna
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (01): : 43 - 49
  • [33] Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities
    Spring, Laura M.
    Nakajima, Erika
    Hutchinson, Jennifer
    Viscosi, Elene
    Blouin, Gayle
    Weekes, Colin
    Rugo, Hope
    Moy, Beverly
    Bardia, Aditya
    ONCOLOGIST, 2021, 26 (10): : 827 - 834
  • [34] Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triplenegative breast cancer (TNBC): Translational investigation
    Bardia, Aditya
    Coates, James T.
    Spring, Laura
    Sun, Sheng
    Juric, Dejan
    Thimmiah, Nayana
    Niemierko, Andrzej
    Ryan, Phoebe
    Partridge, Ann
    Peppercorn, Jeffrey
    Parsons, Heather
    Wander, Seth
    Pierce, Kelsey
    Attaya, Victoria
    Fitzgerald, Donna
    Lormil, Brenda
    Shellock, Maria
    Nagayama, Aiko
    Bossuyt, Veerle
    Moy, Bev
    Tolaney, Sara
    Ellisen, Leif
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
    Hanna, Daire
    Merrick, Sophie
    Ghose, Aruni
    Devlin, Michael John
    Yang, Dorothy D.
    Phillips, Edward
    Okines, Alicia
    Chopra, Neha
    Papadimatraki, Elisavet
    Ross, Kirsty
    Macpherson, Iain
    Boh, Zhuang Y.
    Michie, Caroline O.
    Swampillai, Angela
    Gupta, Sunnia
    Robinson, Tim
    Germain, Lewis
    Twelves, Chris
    Atkinson, Charlotte
    Konstantis, Apostolos
    Riddle, Pippa
    Cresti, Nicola
    Naik, Jay D.
    Borley, Annabel
    Guppy, Amy
    Schmid, Peter
    Phillips, Melissa
    BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1916 - 1920
  • [36] Metastatic triple-negative Breast Cancer (mTNBC) First-in-class Therapy with Sacituzumab Govitecan
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 64 - 65
  • [37] New Data for Sacituzumab Govitecan-hziy in the Treatment of Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 723 - 725
  • [38] Sacituzumab govitecan: a new antibody-drug conjugate for metastatic triple-negative breast cancer
    Banys-Paluchowski, M.
    Krawczyk, Natalia
    ONKOLOGE, 2021, 27 (03): : 287 - 290
  • [39] Sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments
    Xu, B.
    Ma, F.
    Wang, S.
    Tong, Z.
    Li, W.
    Wu, X.
    Wang, X.
    Sun, T.
    Pan, Y.
    Yao, H.
    Wang, X.
    Luo, T.
    Yang, J.
    Zeng, X.
    Zhao, W.
    Cong, X. J.
    Chen, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S650 - S650
  • [40] Metastatic triple-negative breast cancer (mTNBC) first-in-class therapy with sacituzumab govitecan
    Schoellmann, Claudia
    BREAST CARE, 2022, 17 (01)
12345